Abstract: The present invention relates to new indolinone compounds and their pharmaceutically acceptable salts and prodrugs for treating and preventing VEGFR related cellular disorders such as cancer.
Abstract: The invention relates to 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, its therapeutic usage for treatment of diseases mediated by EGFR kinase and its combinatory therapeutic usage together with other therapeutic agents. The invention also provides synthetic methods for preparation of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, and the relevant synthetic intermediates for synthesis of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride.
Type:
Application
Filed:
July 7, 2009
Publication date:
July 28, 2011
Applicant:
Beta Pharma, Inc.
Inventors:
Yinxiang Wang, Guojian Xie, Lieming Ding, Fenlai Tan, Yunyan Hu, Wei He, Bin Han, Wei Long, Yong Liu, Haima Ai, Charles Davis, Don Zhang
Abstract: The present invention is directed to a compound having the structure wherein A is a 7–18 membered ring that comprises 0 to 6 heteroatoms selected from O, S, and N; R1 is selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-8alkyl, substituted or unsubstituted C2-8alkenyl, substituted or unsubstituted C2-8alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocyclyl; m is an integer from 0 to 3; X is selected from the group consisting of NR2, CHR3, O, or S; wherein R2 and R3 are each individually H or C1-8alkyl; R is selected from the group consisting of unsubstituted aryl, and substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl-(C1-3)alkyl, substituted or unsubstituted aryl-(C3-7)cycloalkyl, substituted or unsubstituted heteroaryl-(C1-3)alkyl, and substituted or unsubstituted heteroaryl-(C3-7)cycloalkyl; and pharmaceutically acceptable salts thereof; with the proviso that if A is
Type:
Grant
Filed:
March 26, 2003
Date of Patent:
July 18, 2006
Assignee:
Beta Pharma, Inc.
Inventors:
Don Zhang, Guojian Xie, Charles Davis, Zhengzhuang Cheng, Hang Chen, Yinxiang Wang, Mehrnaz Kamal